43 results
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
be rendered less competitive and sales may decrease; or
Ocuphire’s reputation may suffer generally both among clinicians and patients.
Any one … of marketing approvals;
damage to relationships with any potential collaborators;
unfavorable press coverage and damage to Ocuphire’s reputation;
refusal
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
OF BUSINESS (WHETHER ACTUAL OR PROSPECTIVE), LOSS OF REPUTATION OR OPPORTUNITY, OR DIMINUTION OF VALUE OR ANY DAMAGES BASED ON ANY TYPE OF MULTIPLE
424B5
twlmcw0j9iod
7 Jun 21
Prospectus supplement for primary offering
4:21pm
424B5
63ot3tj0pw4nsph
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B4
p46o6
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K
EX-10.4
hmjnvv1 8fmcr7dm26u
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-14.1
5codh66 gs8
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
qb7xf3w
2 Oct 20
Prospectus supplement
9:25am
S-4/A
t6k onhs0
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
S-4
EX-10.31
oo4m6eco1c1qjgxo
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm
S-4
0t6wdaw 8b8
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm
8-K
EX-10.1
xy2ne9d
19 Jun 20
Rexahn and Ocuphire Enter into Definitive Merger Agreement
9:02am